Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

November 30, 2003

Primary Completion Date

January 31, 2006

Study Completion Date

January 31, 2006

Conditions
Liver TransplantationHepatitisCholestasisCarcinoma, Hepatocellular
Interventions
DRUG

IDN-6556

DRUG

Placebo

Trial Locations (13)

10029

Mount Sinai School of Medicine, New York

45267

University of Cincinnati, Cincinnati

46202

Indiana University Medical Center, Indianapolis

55101

Abteilung für Transplantationschirurgie Johannes Gutenberg-Universität Mainz, Mainz

55905

Mayo Clinic Rochester, Rochester

70112

Tulane University Hospital and Clinic, New Orleans

75246

Baylor Regional Transplant Institute, Baylor University Medical Center, Dallas

78229

The University of Texas Health Science Center at San Antonio, San Antonio

85054

Mayo Clinic Scottsdale, Phoenix

90095

University of California Los Angeles, Los Angeles

94143

University of California San Francisco, San Francisco

D-13353

Oberarzt der Klinik für Allgemein-, Viszeral- und Transplantationschirurgie Charité-Virchow, Berlin

D-30623

Klinik für Viszeral- und Transplantationschirurgie Medizinische Hochschule Hannover, Hanover

Sponsors
All Listed Sponsors
collaborator

Idun Pharmaceuticals

INDUSTRY

lead

Conatus Pharmaceuticals Inc.

INDUSTRY

NCT00080236 - Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation | Biotech Hunter | Biotech Hunter